By Adam Andrzejewski for RealClearPolicy
Because the U.S. was scrambling to get its palms on sufficient Covid-19 speedy antigen checks, it gave a $10.3 million grant to a South Korean biotech firm to assist develop a brand new take a look at. Now, the state of Utah has stopped utilizing the take a look at due to how inaccurate it’s.
In response to an investigation by Judicial Watch, the U.S. Division of Well being and Human Companies gave the funding to South Korean biotech firm GenBody.
Utah began utilizing it in its state-run testing websites in December 2021. Then, in February 2022, Utah paused its use after discovering out that its false detrimental fee was about 60 %. Whereas speedy checks are sometimes much less correct than PCR — polymerase chain response — checks, the excessive inaccuracy fee made the checks ineffective.
RELATED: Unions Wrongly Obtained $36.7 Million In PPP Federal Covid Support
Each time cash is given for analysis and improvement, there’s an opportunity the brand new product gained’t work. However why did a take a look at with a 40 % accuracy fee obtain FDA approval?
It’s additionally price questioning why this cash went to a South Korean agency. The U.S. has a number of the most sensible scientists and most superior biotech firms on the planet. Why did that cash have to depart the U.S.?
With all of the misinformation, combined indicators, and confusion across the dealing with of the Covid-19 pandemic, the American individuals deserve clear and clear data from their authorities.
Assist Conservative Voices!
Signal as much as obtain the most recent political information, perception, and commentary delivered on to your inbox.
Syndicated with permission from Actual Clear Wire.
The #WasteOfTheDay is introduced by the forensic auditors at OpenTheBooks.com.
The opinions expressed by contributors and/or content material companions are their very own and don’t essentially mirror the views of The Political Insider.